emerg
novel
coronaviru
wuhan
china
caus
sever
respiratori
tract
infect
human
emerg
novel
coronaviru
wuhan
china
caus
sever
respiratori
tract
infect
human
covid
becom
global
health
concern
coronavirus
infect
anim
evolv
strain
also
infect
human
recent
show
intraven
immunoglobulin
ivig
treatment
reduc
inflamm
intestin
epitheli
cell
elimin
overgrowth
opportunist
human
fungal
pathogen
candida
albican
murin
gut
associ
downregul
proinflammatori
mediat
combin
upregul
antiinflammatori
cytokin
coronavirus
envelop
positivestrand
rna
virus
belong
famili
coronavirida
envelopeanchor
spike
protein
promot
coronaviru
entri
host
cell
first
bind
host
receptor
fuse
viral
host
membran
wholegenom
sequenc
viral
rna
reveal
viru
caus
phylogenet
relat
sarsrel
coronavirus
first
isol
chines
horsesho
bat
research
guangzhou
china
recent
suggest
pangolin
probabl
anim
sourc
outbreak
term
interact
viru
host
lu
et
al
report
angiotensinconvert
enzym
ace
probabl
use
spike
protein
viru
receptor
similar
sarscov
recent
tang
et
al
show
evolv
two
major
lineagesdub
l
type
older
stype
appear
milder
less
infecti
ltype
emerg
later
spread
quickli
current
aggress
stype
current
symptom
report
patient
includ
mild
sever
respiratori
ill
fever
fatigu
cough
myalgia
difficulti
breath
tyrrel
et
al
show
infect
respiratori
epitheli
cell
coronaviru
becom
vacuol
show
damag
cilia
lead
product
inflammatori
mediat
increas
nasal
secret
caus
local
inflamm
swell
respons
turn
stimul
sneez
obstruct
airway
rais
temperatur
mucosa
current
singl
specif
vaccin
effect
antivir
therapi
sever
pharmaceut
biotechnolog
compani
work
vaccin
develop
estim
vaccin
take
year
develop
test
reach
larg
popul
addit
current
approv
treatment
coronaviru
diseas
includ
sever
antivir
drug
test
initi
find
expect
soon
individu
weaken
immun
system
appear
greater
risk
develop
complic
associ
immunotherapi
use
igg
combin
antivir
drug
could
use
treat
prevent
strengthen
immun
respons
viru
igg
antibodi
includ
two
function
portion
f
ab
fragment
respons
antigen
recognit
crystalliz
fragment
fc
import
activ
immun
respons
interact
receptor
bcell
innat
immun
cell
fc
fragment
also
play
import
role
activ
complement
clearanc
microorgan
ivig
pool
igg
thousand
healthi
donor
exposur
individu
donor
endem
infecti
diseas
vaccin
ubiquit
microorgan
particip
product
igg
antibodi
differ
microorgan
product
ivig
use
treat
patient
autoimmun
chronic
inflammatori
diseas
dermatomyos
kawasaki
diseas
multipl
sclerosi
lupu
chronic
lymphocyt
leukemia
idiopath
thrombocytopen
purpura
furthermor
ivig
also
use
antiinfecti
agent
virus
bacteria
fungi
human
patient
experiment
model
ivig
treatment
may
result
advers
event
associ
specif
immunoglobulin
prepar
individu
differ
mani
clinic
experiment
studi
show
switch
ivig
subcutan
immunoglobulin
minim
advers
event
ivig
play
import
role
prevent
infecti
episod
primari
immunodefici
patient
benefici
effect
antibodi
treatment
infecti
diseas
goe
beyond
simpl
neutral
microorgan
toxin
antiinflammatori
pathway
also
critic
protect
infect
ivig
may
modul
immun
respons
via
multipl
mechan
includ
block
wide
array
proinflammatori
cytokin
fcgamma
receptor
leukocyt
adhes
molecul
suppress
pathogen
subset
neutral
pathogen
autoantibodi
ivig
also
expand
regulatori
tcell
induct
prostaglandin
product
dendrit
cell
studi
ivig
treatment
reduc
intestin
inflamm
decreas
escherichia
coli
enterococcu
faecali
c
albican
popul
gut
mice
overgrowth
e
coli
e
faecali
popul
known
involv
dysbiosi
gut
microbiota
inflammatori
bowel
diseas
ibd
chronic
inflammatori
condit
gastrointestin
tract
also
show
benefici
effect
ivig
associ
suppress
inflammatori
cytokin
enhanc
antiinflammatori
cytokin
gut
addit
ivig
therapi
also
led
increas
express
ligandactiv
transcript
factor
mediat
antiinflammatori
function
resolut
inflamm
express
mediat
inflammatori
respons
reduc
gener
sera
virtual
healthi
adult
contain
anticoronaviru
antibodi
pyrc
et
al
show
human
sera
healthi
adult
inhibit
infect
addit
report
ivig
also
neutral
boukhvalova
et
al
show
contrast
commerci
avail
polyclon
therapeut
igg
product
ivig
obtain
donor
hightit
antibodi
respiratori
syncyti
viru
rsv
great
potenti
improv
outcom
rsv
infect
immunocompromis
subject
control
viral
replic
also
reduc
damag
lung
parenchyma
epitheli
airway
line
current
effort
prevent
spread
far
inadequ
immunotherapi
igg
employ
neutral
viru
caus
effici
igg
would
better
immun
igg
antibodi
collect
patient
recov
citi
surround
area
donor
subject
natur
confront
viru
immun
igg
collect
europ
usa
may
differ
collect
china
lifestyl
diet
environ
play
import
role
develop
specif
antibodi
viru
recent
research
sacco
univers
hospit
milan
itali
announc
isol
new
strain
coronaviru
italian
patient
show
genet
differ
compar
origin
strain
isol
china
idea
treat
infect
patient
immun
igg
collect
citi
order
increas
chanc
neutral
viru
differ
procedur
may
use
remov
inactiv
possibl
pathogen
plasma
recov
coronaviru
patient
deriv
immun
igg
includ
solventdeterg
c
heat
treatment
nanofiltr
nm
terpstra
et
al
show
nm
filtrat
step
combin
pepsin
solventdeterg
treatment
contribut
viruselimin
liquid
intraven
immunoglobulin
overal
immunotherapi
immun
igg
combin
antivir
drug
could
provid
altern
treatment
immun
igg
antibodi
collect
recov
patient
specif
boost
immun
respons
newli
infect
patient
although
vaccin
current
avail
combin
immun
igg
antibodi
antivir
drug
offer
shortterm
mediumterm
solut
fund
work
partial
fund
agenc
national
de
la
recherch
anr
set
project
innatefun
promot
refer
infectera
program
author
declar
conflict
interest
